Dihydrotetrabenazine

Dihydrotetrabenazine
Identifiers
CAS Number
3D model (JSmol)
ChemSpider
PubChem CID
InChI
  • InChI=1S/C19H29NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16-17,21H,5-7,10-11H2,1-4H3
    Key: WEQLWGNDNRARGE-UHFFFAOYSA-N
SMILES
  • COC1=C(OC)C=C(C(CC(O)C(CC(C)C)C2)N2CC3)C3=C1
Properties
Chemical formula
 C19H29NO3
Molar mass 319.445 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Dihydrotetrabenazine or DTBZ is an organic compound with the chemical formula C19H29NO3. It is a close analog of tetrabenazine. DTBZ and its derivatives, when labeled with positron emitting isotopes such as carbon-11 and fluorine-18, are used as PET radioligands for examining VMAT2.[1]

Use in Positron Emission Tomography

Carbon-11 labeled (+)DTBZ(right) and fluorine-18 labeled fluoropropylated (+)DTBZ(left)
Reconstructed data from PET scan of healthy human brain using [18F]Fluoropropyl-DTBZ indicating VMAT2 distribution[2]

[11C]DTBZ as a PET radioligand with affinity for VMAT2 was developed in the mid 1990s by David E. Kuhl and colleagues at the University of Michigan.[3] There are two enantiomers of alpha-dihydrotetrabenazine, and the dextrorotary(or (+) isomer) has a high affinity of about 1 nanomolar Ki whereas the levorotary (or (-) isomer) has approximately 1000 fold lower affinity with a Ki of about 2 micromolar.[4]

VMAT2 is a membrane bound protein and a biomarker for Parkinson's disease. Binding of DTBZ to VMAT2 in individuals with Parkinson's disease is significantly reduced.[5] Moreover, the VMAT2 density as determined by [18F]DTBZ has been shown to be well, inversely correlated with the severity of Parkinson's disease.[6]

Avid Radiopharmaceuticals has sponsored clinical trials of [18F]AV-133 (or [18F]Fluoropropyl-(+)-DTBZ) to identify subjects with dopaminergic degeneration.[7]

See also

References

  1. ↑ Koeppe, RA; Gilman, S; Joshi, A; Liu, S; Little, R; Junck, L; Heumann, M; Frey, KA; Albin, RL (June 2005). "11C-DTBZ and 18F-FDG PET measures in differentiating dementias". Journal of Nuclear Medicine. 46 (6): 936–44. PMID 15937303.
  2. ↑ Lin, KJ; Weng, YH; Hsieh, CJ; Lin, WY; Wey, SP; Kung, MP; Yen, TC; Lu, CS; Hsiao, IT (2013). "Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET". PLOS ONE. 8 (9): e75952. doi:10.1371/journal.pone.0075952. PMC 3786914. PMID 24098749.
  3. ↑ Frey, KA; Koeppe, RA; Kilbourn, MR; Vander Borght, TM; Albin, RL; Gilman, S; Kuhl, DE (December 1996). "Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging" (PDF). Annals of Neurology. 40 (6): 873–84. doi:10.1002/ana.410400609. hdl:2027.42/50362. PMID 9007092. S2CID 9419161.
  4. ↑ Kilbourn, M; Lee, L; Vander Borght, T; Jewett, D; Frey, K (24 May 1995). "Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific". European Journal of Pharmacology. 278 (3): 249–52. doi:10.1016/0014-2999(95)00162-e. PMID 7589162.
  5. ↑ Wang, Jian; Hoekstra, Jake G.; Zuo, Chuantao; Cook, Travis J.; Zhang, Jing (February 2013). "Biomarkers of Parkinson's disease: current status and future perspectives". Drug Discovery Today. 18 (3–4): 155–162. doi:10.1016/j.drudis.2012.09.001. PMC 3557745. PMID 22982303.
  6. ↑ Hsiao, Ing-Tsung; Weng, Yi-Hsin; Hsieh, Chia-Ju; Lin, Wey-Yil; Wey, Shiaw-Pyng; Kung, Mei-Ping; Yen, Tzu-Chen; Lu, Chin-Song; Lin, Kun-Ju (1 June 2014). "Correlation of Parkinson Disease Severity and F-DTBZ Positron Emission Tomography". JAMA Neurology. 71 (6): 758–766. doi:10.1001/jamaneurol.2014.290. PMID 24756323.
  7. ↑ "A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders". Clinical Trials. U.S. National Institutes of Health. Retrieved 20 July 2015.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.